Moreover, considering the high heterogeneity in CD44 isoforms expressed by CSCs, which has been documented in breast cancer [242], it is also plausible that regulation of CD44 splicing may allow CSCs to maintain the hybrid E/M state that has been correlated with higher stemness and tumorigenicity [51, 243]. The gene discussed is CD44; the disease is breast cancer.